ArticleMolecular pain
Ascorbic acid relieves neuropathic pain and depressive behavior by reducing inflammation and activating antioxidant responses.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain (NP), a specific subtype of chronic pain, can induce depression-like behavior, presenting significant challenges for clinical treatment. Ascorbic acid (AA) is a free radical scavenger; however, its regulatory effects on NP, particularly within the spinal cord, remain ambiguous. In this research, we examined the impact of AA on NP and associated depression-like behavior by establishing a spinal nerve injury (SNI) NP model. Behavioral tests showed that mice in the SNI group exhibited hyperalgesia and depression-like behavior. Compared with the control group, the SNI group showed attenuated antioxidant responses (impaired Nrf2 signaling), excessive NLRP3 inflammasome activation, and elevated AMPK activity in spinal cord tissues. However, treatment with AA alleviated NP and depression-like behavior in mice with SNI by suppressing NLRP3-mediated inflammation and enhancing Nrf2-driven antioxidant responses. In vivo electrophysiology demonstrated that AA reversed the increase in theta, alpha, and beta band energies in mice with SNI. The results suggest that AA mitigates NP and comorbid depression-like behavior by inhibiting the activity of NLRP3 inflammasome and activating the Nrf2 pathway. Its ability to normalize neurophysiological rhythms further supports its therapeutic potential for NP. These findings imply that AA is a novel therapeutic agent for NP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.